NX-0101
Origination desk
Asset intake & structuring
Technical and legal due diligence on each scientific asset before it is admitted for negotiation: TRL validation, IP chain of title, regulatory pathway and independent valuation.
Nexus Exchange
The negotiation infrastructure behind the marketplace.
Nexus operates as the economic layer of AXIOM — origination, price formation, capital raising, fiscal engineering, compliance and settlement, including two fully tokenised assets.
Instruments admitted
Under evaluation
Pre-raise — no instruments negotiated yet
Notional in book
Not applicable
No live order book yet
Tokenised assets (planned)
2
AURA · NXST
Settlement cycle (design)
T+5
Escrow, registry and audited release — not yet operational
Market structure
Six desks, one chain of custody.
Every operation crosses the same sequence: it is originated, priced, funded, framed fiscally, controlled for risk and settled with documentary evidence.
NX-0202
Trading desk
Price formation & matching
Bilateral and auction-based negotiation of licences, royalty streams and equity tranches, with indicative books, reference pricing and a documented audit trail per order.
NX-0303
Capital markets desk
Fundraising & syndication
Structures rounds, convertible notes, royalty financing and token offerings; assembles syndicates of corporates, funds, family offices and development institutions.
NX-0404
Fiscal engineering desk
Lei do Bem & incentives
Frames each operation inside Lei do Bem, Art. 19/19-A, EMBRAPII and FINEP, converting eligible R&D spend into fiscal return with an audit-ready defence dossier.
NX-0505
Custody & settlement
Post-trade
Escrow of contracts and funds, registry of licence rights, on-chain settlement for tokenised assets and quarterly reconciliation of royalty flows.
NX-0606
Risk & compliance desk
Market integrity
KYC/KYB, AML screening, suitability, conflict-of-interest walls, sanctions checks and surveillance of every negotiation before release to settlement.
Trading desk
Indicative book of admitted instruments.
Illustrative reference levels. Firm quotes, allocation and documentation are released to verified counterparties in the Data Room.
| Instrument | Asset | Type | Bid | Ask | Last | Δ | Status |
|---|---|---|---|---|---|---|---|
| No live order book yet — AXIOM is pre-raise. This structure will populate once instruments are admitted to negotiation. | |||||||
Values in US$ million, except tokens, quoted in US$ per unit. Nothing on this page constitutes an offer or investment recommendation.
Capital raising
Five instruments to fund validated science.
EQ
Equity & convertible notes
Ticket
US$ 2M – 30M
Horizon
5 – 8 years
Direct participation in the spin-out holding the asset, with governance rights, anti-dilution and milestone-linked tranches.
RF
Royalty financing
Ticket
US$ 1M – 15M
Horizon
4 – 10 years
Capital advanced against a defined share of future royalties, with quarterly accounting, audit rights and a contractual cap on total return.
LC
Licence with upfront + milestones
Ticket
US$ 0.5M – 25M
Horizon
Per contract
Corporate acquires territorial or field-of-use rights; consideration split between upfront, development milestones and running royalties.
FI
Non-dilutive public funding
Ticket
R$ 1M – 60M
Horizon
2 – 6 years
FINEP, BNDES, EMBRAPII and FAPESP lines combined with Lei do Bem framing to reduce the effective cost of the R&D programme.
TK
Tokenised offering
Ticket
US$ 250k – 10M
Horizon
Continuous
Fractional exposure to a basket of validated assets through AURA and NXST, with on-chain registry and off-chain legal backing.
Lei do Bem models
Five structuring models, one evidence standard.
Each negotiated operation is mapped to the model that frames it, so the fiscal benefit is defensible before the tax authority.
Internal R&D programme
- Who it fits
- Corporate under Lucro Real with in-house teams
- Mechanics
- Exclusion of 60% to 100% of eligible expenditure from IRPJ/CSLL taxable base, allocated by project and cost centre.
- Evidence required
- Project charter, timesheets, technical uncertainty report, FORMP&D dossier.
Contracted ICT co-development
- Who it fits
- Corporate contracting a university or research institute
- Mechanics
- Eligible spend includes ICT service contracts; IP split agreed upfront and reflected in the royalty schedule.
- Evidence required
- Bilateral agreement, ICT technical reports, invoices tied to project codes.
Licence-in plus development
- Who it fits
- Corporate licensing an AXIOM asset and continuing R&D
- Mechanics
- Upfront licence fee is not eligible; subsequent development, trials and scale-up spend is framed as eligible R&D.
- Evidence required
- Licence agreement, post-licence development plan, segregated cost ledger.
Art. 19-A grant to ICT
- Who it fits
- Corporate funding an accredited ICT project
- Mechanics
- Up to 2x the transferred amount excluded from taxable base, subject to MCTI accreditation and project approval.
- Evidence required
- MCTI accreditation, transfer proof, ICT execution report, no-IP-transfer clause.
Consortium / shared programme
- Who it fits
- Two or more corporates sharing a pre-competitive agenda
- Mechanics
- Each participant claims its own share of eligible expenditure; results and IP allocated by contribution matrix.
- Evidence required
- Consortium agreement, contribution matrix, independent programme audit.
Market compliance
No order clears without controls.
| Ref. | Domain | Requirement | Control |
|---|---|---|---|
| MC-01 | KYC / KYB onboarding | Identification of counterparties, ultimate beneficial owners and source of funds before any book access. | Tiered onboarding with periodic re-verification |
| MC-02 | AML & sanctions screening | Continuous screening against sanctions, PEP and adverse media lists; reporting of atypical operations. | Automated screening + human review of alerts |
| MC-03 | Suitability & investor profile | Deep-tech and tokenised exposure offered only to qualified or professional investors, matched to declared risk profile. | Profile questionnaire with hard blocks |
| MC-04 | Securities & token classification | Legal opinion per instrument on whether it constitutes a security, with CVM regime mapping and offering restrictions. | Instrument register with regime tags |
| MC-05 | Market surveillance | Detection of self-dealing, front-running and coordinated pricing across the negotiation layer. | Order-level audit trail, immutable log |
| MC-06 | Disclosure & conflict walls | Separation between origination, valuation and trading; disclosure of related-party interest in any asset. | Information barriers, quarterly attestations |
Custody & settlement
From signature to distribution.
- 01
Order confirmation
Both counterparties sign the term sheet electronically; the order is locked and timestamped in the audit log.
- 02
Escrow funding
Funds are deposited with the escrow agent; fiscal framing and incentive eligibility are confirmed before release.
- 03
Rights registry
Licence, royalty or equity rights are recorded in the Nexus registry and, for tokenised assets, minted on-chain.
- 04
Backing audit
Independent auditor reconciles token supply against the legal backing and publishes an attestation each quarter.
- 05
Distribution
Royalty and milestone flows are calculated, withheld for taxes and distributed pro rata to holders of record.
Tokenised assets
Two instruments, fully tokenised.
AURAPre-raise
Aura Finance Token
Turns illiquid, long-dated royalty contracts into fractional, transferable exposure — the cash-flow layer of the exchange.
NXSTPre-raise
Nexus Science Token
One instrument for diversified exposure to the whole exchange instead of a single asset — the index layer of the platform.